NCT01820832

Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD

Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The safety and efficacy of Caltriol on mild proteinuria (\<1.0g/d) reduction in CKD patients.

Detailed description

Proteinuria is not only a capital sign of kidney disease, but also a marker of chronic kidney disease (CKD) progression. Emerging evidence in patients with CKD show that vitamin D and its analogs can reduce proteinuria or albuminuria in the presence of angiotensin-converting enzyme inhibithion. While some of the studies reported that vitamin D receptor activation has been associated with increased serum creatinine and reduced estimated glomerular filtration rates. Therefore, the investigators plan to conduct a randomized clinical study to evaluate the efficacy and safety of Calcitriol in the treatment of mild proteinuria (\<1.0g/d) CKD patients,which has no specific treatment at present.

Conditions

• Chronic Kidney Disease
• Proteinuria

Interventions

Type	Name	Description
DRUG	Calcitriol	Calcitriol 0.5 ug/BIW for 24 weeks.

Timeline

• Start date: 2013-03-01
• Primary completion: 2014-12-01
• Completion: 2015-06-01
• First posted: 2013-03-29
• Last updated: 2013-03-29

Locations

1 site across 1 country: China